TABLE 1. Median and range of number of studies in literature review related to perinatal hepatitis C testing, prevalence, and linkage to care, by selected characteristics — United States, 2023.
| Characteristic | Median % (IQR) | Range, % | No. of studies guiding estimates |
|---|---|---|---|
|
Pregnant
persons*
| |||
| Proportion tested for
HCV |
47.6 (10.2–80.9) |
0.7–98.4 |
16 |
| Prevalence of reactive
anti-HCV or diagnosis |
1.1 (0.4–30.9) |
0.1–70.8 |
35 |
| Prevalence of detectable
HCV RNA† |
68.2 (61.5–77.2) |
29.6–81.3 |
11 |
|
Perinatally exposed children
| |||
| Proportion referred for HCV
testing |
16.7
(NA)§ |
1.9–31.4 |
2 |
| Proportion tested for
HCV¶ |
30.1 (20.3–44.5) |
8.6–53.1 |
12 |
| Rate of perinatal
transmission |
4.7 (3.2–7.4) |
0.0–11.1 |
13 |
| Proportion of infected
children linked to care** |
100% (NA) |
NA |
1 |
| Proportion of children with CHC who achieved SVR12 after DAA treatment | 98.1 (97.1–98.9) | 96-100 | 7 |
Abbreviations: anti-HCV = hepatitis C virus antibody; CHC = chronic hepatitis C; DAA = direct-acting antiviral; HCV = hepatitis C virus; IQR = interquartile range; NA = not available; NAT = nucleic acid test; SVR12 = sustained virologic response 12 weeks posttreatment.
* All estimates among pregnant persons include studies reviewed in Source: Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR Recomm Rep 2020;69:1–17.
† HCV RNA detected among those who are anti-HCV reactive.
§ No IQR available because only two studies.
¶ Perinatally exposed children tested with an anti-HCV test or a NAT for HCV RNA.
** Children who received a diagnosis of perinatal hepatitis C who attended an HCV-related appointment.